Статья

Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity

M. Pykhtina, S. Miroshnichenko, V. Romanov, A. Grazhdantseva, G. Kochneva, A. Beklemishev,
2021

In this study, two strains of the yeast P. pastoris were constructed, one of which produced authentic recombinant human granulocyte-macrophage colony-stimulating factor (ryGM-CSF), and the other was a chimera consisting of ryGM-CSF genetically fused with mature human apolipoprotein A-I (ApoA-I) (ryGM-CSF-ApoA-I). Both forms of the cytokine were secreted into the culture medium. The proteins' yield during cultivation in flasks was 100 and 60 mg/L for ryGM-CSF and ryGM-CSF-ApoA-I, respectively. Both forms of recombinant GM-CSF stimulated the proliferation of human TF-1 erythroleukemia cells; however, the amount of chimera required was 10-fold that of authentic GM-CSF to induce a similar proliferative effect. RyGM-CSF exhibited a 2-fold proliferative effect on BFU-E (burst-forming units-erythroid) at a concentration 1.7 fold less than non-glycosylated E. coli-derived GM-CSF. The chimera together with authentic ryGM-CSF increased the number of both erythroid precursors and BMC granulocytes after 48 h of incubation of human bone marrow cells (BMCs). In addition, the chimeric form of ryGM-CSF was more effective at increasing the viability of the total amount of BMCs, decreasing apoptosis compared to the authentic form. ryGM-CSF-ApoA-I normalized the proliferation, maturation, and segmentation of neutrophils within the physiological norm, preserving the pool of blast cells under conditions of impaired granulopoiesis. The chimera form of GM-CSF exhibited the properties of a multilinear growth factor, modulating the activity of GM-CSF and, perhaps, it may be more suitable for the normalization of granulopoiesis.

Цитирование

Похожие публикации

Версии

  • 1. Version of Record от 2021-05-13

Метаданные

Об авторах
  • M. Pykhtina
    Institute of Biochemistry of Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Novosibirsk, 2 Timakova Street, Novosibirsk 630117, Russia;, Pykhtina_maria@mail.ru, (M.P.);, svmiro@yandex.ru, (S.M.);, vprom@mail.ru, (V.R.)
  • S. Miroshnichenko
    Institute of Biochemistry of Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Novosibirsk, 2 Timakova Street, Novosibirsk 630117, Russia;, Pykhtina_maria@mail.ru, (M.P.);, svmiro@yandex.ru, (S.M.);, vprom@mail.ru, (V.R.)
  • V. Romanov
    Institute of Biochemistry of Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Novosibirsk, 2 Timakova Street, Novosibirsk 630117, Russia;, Pykhtina_maria@mail.ru, (M.P.);, svmiro@yandex.ru, (S.M.);, vprom@mail.ru, (V.R.)
  • A. Grazhdantseva
    Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Novosibirsk 630559, Russia;, gaa@vector.nsc.ru, (A.G.);, g.v.kochneva@yandex.ru, (G.K.)
  • G. Kochneva
    Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Novosibirsk 630559, Russia;, gaa@vector.nsc.ru, (A.G.);, g.v.kochneva@yandex.ru, (G.K.)
  • A. Beklemishev
    Institute of Biochemistry of Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Novosibirsk, 2 Timakova Street, Novosibirsk 630117, Russia;, Pykhtina_maria@mail.ru, (M.P.);, svmiro@yandex.ru, (S.M.);, vprom@mail.ru, (V.R.)
Название журнала
  • Pharmaceuticals
Том
  • 14
Выпуск
  • 5
Страницы
  • 459
Издатель
  • MDPI
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • dimensions